21 / 22
Page 52
Volume 2
Journal of Microbiology and Biotechnology Reports
Microbial Biotechnology 2018
September 17-18, 2018
Microbial Biotechnology & Vaccine Design
September 17-18, 2018 Lisbon, Portugal
5
th
World Congress on
Colon cancer stem cell-based vaccine reduces efficiently both tumor growth and cancer stem cell
subpopulation in a mouse colon carcinoma mouse model
Jun Dou, Mei Guo, Fengshu Zhao, Di Wu, Miao Li, Meng Pan, Jing Wang and Fangfang Shi
Southeast University, China
Statement of the Problem:
Colon cancer is the most common malignant gastrointestinal cancers that are still the most frequent
cause of cancer-related mortality in China. Colon Cancer Stem Cells (CCSCs) are the main reasons that result in the drug and
radiation resistance, invasive growth, metastasis and cancer relapse. Though many factors involving immuno surveillance and
immunosuppression were recently validated as important for patient prognosis, a lot of experimental immunotherapies to fight
unresectable metastatic colorectal cancer, only few cases have successfully induced antitumor immune response against malignancies.
The aim of this work was to investigate the effects on the inhibition of colon cancer growth by vaccination of CCSC vaccines.
Method:
The CD133
+
CSCs were isolated from human LOVO and mouse CT26 cell lines by using a magnetic-activated cell sorting
system, respectively. The xenograft or syngeneic mice were subcutaneously inoculated with the LOVO or CT26 CD133
+
CSC
vaccine inactivated with again and again freeze thawing three times before the mice were challenged subcutaneously with LOVO
or CT26 cells. The inhibition tumor efficacy was assessed by the tumorigenicity, immune efficient analysis by flow cytometer and
enzyme-linked immunosorbent assays, respectively.
Result:
The results showed that, compared with the non-CSC vaccine, the inhibition tumor growth efficacy of LOVO or CT26 CSC
vaccine was significantly increased in the xenograft or syngeneic mice. Vaccination of LOVO or CT26 CD133
+
CSC vaccine resulted
in increasing cytotoxic activity of natural killer cells, enhancing serum IFN-γ and decreasing TGF- β levels in the mice. The LOVO
and CT26 CD133
+
CSC vaccines significantly reduced the CSC subpopulations in the colon cancer tissues.
Conclusion:
The data provided the first evidence that the human LOVO or mouse CT26 CD133
+
CSC-based vaccine may be an
attractive therapeutic approach to excitation of anti-tumor immunity for treatment of colon cancer.
njdoujun@seu.edu.cnJun Dou et al., J Microbio and Biotech Rept 2018, Volume 2